What is Tango Therapeutics's less than 12 months?

Tango Therapeutics (TNGX) reported less than 12 months of $154.03M in Q1 2026.

How has Tango Therapeutics's less than 12 months changed year-over-year?

Tango Therapeutics's less than 12 months increased by 170.9% year-over-year, from $56.85M to $154.03M.

What is the long-term trend for Tango Therapeutics's less than 12 months?

Over 3 years (2021 to 2024), Tango Therapeutics's less than 12 months has grown at a -48.1% compound annual growth rate (CAGR), from $329.71M to $46.02M.

Tango Therapeutics TNGX Less than 12 months

Less than 12 months at other companies

Gilead SciencesGILD

——

ExelixisEXEL

——

ModernaMRNA

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

See full

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

See full

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

See full

Market cap$4.55B+1,915%

Profitability

See full

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

See full

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's less than 12 months.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tango Therapeutics's less than 12 months?: Tango Therapeutics (TNGX) reported less than 12 months of $154.03M in Q1 2026.
How has Tango Therapeutics's less than 12 months changed year-over-year?: Tango Therapeutics's less than 12 months increased by 170.9% year-over-year, from $56.85M to $154.03M.
What is the long-term trend for Tango Therapeutics's less than 12 months?: Over 3 years (2021 to 2024), Tango Therapeutics's less than 12 months has grown at a -48.1% compound annual growth rate (CAGR), from $329.71M to $46.02M.